These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 38403067)

  • 21. Metabolic dysfunction-associated steatotic liver disease prevalence and risk factors in inflammatory bowel disease in tertiary center.
    Oliveira LDRP; Ribeiro TCDR; Mourao Junior CA; Barra MAL; Silva MHG; Shafee LP; Zacarias SM; Campos LDC; Valério HMG; Chebli JMF
    Rev Assoc Med Bras (1992); 2024; 70(6):e20231321. PubMed ID: 39045949
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Liver fibrosis in non-alcoholic fatty liver disease - diagnostic challenge with prognostic significance.
    Stål P
    World J Gastroenterol; 2015 Oct; 21(39):11077-87. PubMed ID: 26494963
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Non-invasive fibrosis scoring systems can predict future metabolic complications and overall mortality in non-alcoholic fatty liver disease (NAFLD).
    Önnerhag K; Hartman H; Nilsson PM; Lindgren S
    Scand J Gastroenterol; 2019 Mar; 54(3):328-334. PubMed ID: 30907181
    [No Abstract]   [Full Text] [Related]  

  • 24. Prevalence of non-alcoholic fatty liver disease and risk factors for advanced fibrosis and mortality in the United States.
    Le MH; Devaki P; Ha NB; Jun DW; Te HS; Cheung RC; Nguyen MH
    PLoS One; 2017; 12(3):e0173499. PubMed ID: 28346543
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Sex differences in prevalence and prognosis of steatotic liver disease phenotypes: Biological sex matters.
    Ji H; Cheng S;
    J Hepatol; 2024 Feb; 80(2):e68-e69. PubMed ID: 37619929
    [No Abstract]   [Full Text] [Related]  

  • 26. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: An update.
    Athyros VG; Tziomalos K; Katsiki N; Doumas M; Karagiannis A; Mikhailidis DP
    World J Gastroenterol; 2015 Jun; 21(22):6820-34. PubMed ID: 26078558
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Metabolic dysfunction-associated fatty liver disease and heavy alcohol consumption increase mortality:A nationwide study.
    Cho SH; Kim S; Oh R; Kim JY; Lee YB; Jin SM; Hur KY; Kim G; Kim JH
    Hepatol Int; 2024 Aug; 18(4):1168-1177. PubMed ID: 38806774
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Epidemiology and Natural History of Nonalcoholic Fatty Liver Disease.
    Satapathy SK; Sanyal AJ
    Semin Liver Dis; 2015 Aug; 35(3):221-35. PubMed ID: 26378640
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Changing Trends in Etiology-Based Annual Mortality From Chronic Liver Disease, From 2007 Through 2016.
    Kim D; Li AA; Gadiparthi C; Khan MA; Cholankeril G; Glenn JS; Ahmed A
    Gastroenterology; 2018 Oct; 155(4):1154-1163.e3. PubMed ID: 30009816
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Phosphatase and tensin homolog is a differential diagnostic marker between nonalcoholic and alcoholic fatty liver disease.
    Sanchez-Pareja A; Clément S; Peyrou M; Spahr L; Negro F; Rubbia-Brandt L; Foti M
    World J Gastroenterol; 2016 Apr; 22(14):3735-45. PubMed ID: 27076758
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Non-Invasive Assessment of Liver Injury in Non-Alcoholic Fatty Liver Disease: A Review of Literature.
    Maida M; Macaluso FS; Salomone F; Petta S
    Curr Mol Med; 2016; 16(8):721-737. PubMed ID: 27719652
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The Repeatedly Elevated Fatty Liver Index Is Associated With Increased Mortality: A Population-Based Cohort Study.
    Lee CH; Han KD; Kim DH; Kwak MS
    Front Endocrinol (Lausanne); 2021; 12():638615. PubMed ID: 33776934
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Evaluating the therapeutic efficacy of NAD supplementation in management of metabolic dysfunction-associated steatotic liver disease: Key considerations.
    Lu X; Yang R; Chen Y; Chen D
    Clin Mol Hepatol; 2024 Jul; 30(3):582-584. PubMed ID: 38163440
    [No Abstract]   [Full Text] [Related]  

  • 34. Epidemiology of fatty liver: an update.
    Bedogni G; Nobili V; Tiribelli C
    World J Gastroenterol; 2014 Jul; 20(27):9050-4. PubMed ID: 25083078
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Mechanisms of Lipid Droplet Accumulation in Steatotic Liver Diseases.
    Dempsey JL; Ioannou GN; Carr RM
    Semin Liver Dis; 2023 Nov; 43(4):367-382. PubMed ID: 37799111
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Nonalcoholic Fatty Liver Disease: Status Quo.
    Sporea I; Popescu A; Dumitrașcu D; Brisc C; Nedelcu L; Trifan A; Gheorghe L; Fierbințeanu Braticevici C
    J Gastrointestin Liver Dis; 2018 Dec; 27(4):439-448. PubMed ID: 30574627
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Novel Multimodal Database for Metabolic Dysfunction-Associated Steatotic Liver Disease-Linking Genes to Outcomes.
    Naimimohasses S; Bhat M
    Gastroenterology; 2024 Jul; 167(2):410-411. PubMed ID: 38485096
    [No Abstract]   [Full Text] [Related]  

  • 38. Trends in hepatocellular carcinoma due to non-alcoholic fatty liver disease.
    Bertot LC; Adams LA
    Expert Rev Gastroenterol Hepatol; 2019 Feb; 13(2):179-187. PubMed ID: 30791782
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis.
    Younossi ZM; Henry L; Bush H; Mishra A
    Clin Liver Dis; 2018 Feb; 22(1):1-10. PubMed ID: 29128049
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Research advances in nonalcoholic fatty liver disease and alcoholic liver disease in 2016].
    Chen YS; Wang BY; Li YM
    Zhonghua Gan Zang Bing Za Zhi; 2017 Mar; 25(3):181-186. PubMed ID: 28482404
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.